Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma
Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention
To study the difference in the proportion of patients with nasopharyngeal carcinoma who lost more than 10% of their body weight within 1 month after radiotherapy and chemotherapy using the mobile platform for whole-process…
- Trial name
- NCT05834712
- Testing
- mobile platform or not mobile platform
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Sun Yat-sen University
Oral Cavity Carcinoma, Oropharyngeal Cancer
Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer
The purpose of this study is to investigate whether the extent of late sequelae symptoms(reduced mouth opening, lymphoedema, decreased range of motion in the neck and shoulder region, speech and swallow disorders and reduced…
- Conditions
- Oral Cavity Carcinoma, Oropharyngeal Cancer, Adverse Effect of Radiation Therapy, Trismus
- Trial name
- HOHF (NCT00780312)
- Testing
- physiotherapy
- Where
- Denmark
- Volunteers
- 97 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Nasopharynx Cancer, Radiotherapy
3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma
Verify that 3DV+TPS is non-inferior compared to existing imported TPS and superior to existing domestic TPS.
- Trial name
- NCT03791944
- Testing
- 3DV+TPS/VARIAN, TPS / VARIAN, 3DV + TPS / Domestic Accelerator
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinqiao Hospital of Chongqing
Nasopharyngeal Carcinoma
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
The investigators propose a phase II randomized-controlled study on using durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab, compared to induction chemotherapy…
- Trial name
- NCT04447612
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- Hong Kong
- Volunteers
- 118 people
- Sponsor
- The University of Hong Kong
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
- Trial name
- SAVAL (NCT06088381)
- Testing
- Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Maryland, Baltimore
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
In order to explore the efficacy and safety of targeted therapy and immunotherapy combined with GP chemotherapy in the treatment of high risk advanced nasopharyngeal carcinoma, the investigators design a single-arm, Phase II…
- Trial name
- NCT06851247
- Testing
- Toripalimab, Anlotinib, Gemcitabine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
The NCCN guidelines recommend induction chemotherapy followed by concurrent chemoradiotherapy as the standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT06301165
- Testing
- TPC induction chemotherapy, GP induction chemotherapy
- Where
- 8 sites in China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC
The purpose of this study is to compare the efficacy and safety of sequential chemoradiotherapy (induction chemotherapy + intensity-modulated radiotherapy +adjuvant chemotherapy) with induction chemotherapy plus concurrent…
- Trial name
- NCT03366415
- Testing
- gemcitabine and cisplatin (Induction and adjuvant chemotherapy), IMRT, gemcitabine and cisplatin (Induction chemotherapy)
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Chaosu Hu
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies the effect of cemiplimab in combination with low-dose paclitaxel and carboplatin in treating patients with squamous cell carcinoma of the head and neck that has come back (recurrent) or spread to other…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT04862650
- Testing
- Carboplatin, Cemiplimab, Paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Marcelo Bonomi
Nasopharyngeal Carcinoma (NPC), Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
This Phase Ib/II study is a clinical trial to evaluate the efficacy and safety of BL-M08D1 for Injection in patients with recurrent or metastatic nasopharyngeal carcinoma and other solid tumors.
- Trial name
- NCT07818486
- Testing
- BL-M08D1
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Nasopharyngeal Carcinoma
Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma
Radiotherapy is an important treatment for initial distant metastases nasopharyngeal carcinoma. Total dose and fraction size are important prognostic factors for survival, although to our knowledge the optimal model has not been…
- Trial name
- NCT03598218
- Testing
- Hypofraction radiation, Standard dose IMRT
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Wei Jiang
Nasopharyngeal Carcinoma
CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients.
- Trial name
- NCT05724355
- Testing
- Dalpiciclib Isetionate Tablets, Camrelizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Obstructive Sleep Apnea-hypopnea, Oropharyngeal Cancer
Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy
The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer.
- Trial name
- COROSAS (NCT04440618)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Poitiers University Hospital
Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma
- Trial name
- NCT02113878
- Testing
- BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Oropharyngeal Squamous Cell Carcinoma
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Pembrolizumab and nivolumab (with or without chemotherapy) are used to treat head and neck cancer. The middle part of the throat (oropharynx) is a common location for head and neck cancer.
- Trial name
- NCT06771674
- Testing
- Pembrolizumab, Nivolumab
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Hookipa Biotech GmbH
Carcinoma, Nasopharyngeal
Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of Nasopharynx
The present study is designed as a two arm randomized trial to evaluate the impact of accelerated radiotherapy delivered by image guided radiotherapy with rapid arc technique in carcinoma nasopharynx.
- Trial name
- EARN (NCT04538547)
- Testing
- Accelerated Radiotherapy, Non Accelerated Radiotherapy
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Nasopharyngeal Carcinoma, Head and Neck Cancer
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year.
- Conditions
- Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
- Trial name
- NCT06307314
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Nasopharyngeal Carcinoma
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma
Local control rates of nasopharyngeal carcinoma are increasing, but 15% of patients still have local recurrence within 5 years after initial treatment.
- Trial name
- NCT04764149
- Where
- China
- Volunteers
- 801 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.